Our Centre is engaged in a collaboration with the “Foundation of Innovative New Diagnostics (FIND)”, the global alliance for diagnostics that is also based in Geneva.
Since 2020, we are conducting analytical and clinical validation studies together of novel diagnostic assays for emerging viruses.
During the Covid-19 pandemic, we have evaluated a large number of molecular assays for the detection of SARS-CoV-2 as well as antigen-detecting rapid diagnostic tests (Ag-RDTs), the latter continuously running in our outpatient testing Centre that was operating until the end of 2022.
Since 2023, clinical validation studies of point of care devices are conducted in the emergence department of the HUG. Since the emergence of “mpox” (formerly named “monkeypox”), we are engaged in a second project on the validation of molecular point of care tests for the virus. All results of our validations are available on the website of FIND under and several of our validations were published as scientific papers.